The Thomas Reiner Lab

The Reiner Lab research program revolves around the development, validation and translation of novel imaging agents. Our research is firmly rooted in the preclinical research space, but we also aggressively pursue translational clinical projects. One of our key achievements is the development of a quantitative small molecule imaging platform for PARP1, yielding several translated imaging agents that have originated in our lab. One of our imaging agents, PARPi-FL, a fluorescent intraoperative probe, entered clinical trials in March 2017 (IND#133,109, NCT03085147). A second translated drug, [18F]PARPi, a quantitative PET imaging agent, was approved for clinical trials in August 2018 and November 2019 (IND#139974; NCT03631017 and NCT04173104, respectively). Phase I data for both agents has been published in Nature Biomedical Engineering (Kossatz et al 2020) and Clinical Cancer Research (Schöder et al, 2020). A radiotherapeutic version of our PARP1 imaging agents is being tested in mouse models of cancer.

While our previous work was in large part focused on the detection, delineation and treatment of cancer, we also interrogate other physiologically relevant markers. These agents help us to understand the molecular mechanisms of drug action, shedding new light on tumor cell pathology and helping to predict why some patients respond well to a particular treatment regimen, while others do not.

Learn more
Pictured: Thomas Reiner

Thomas Reiner, PhD

Associate Professor

Research Focus

Imaging specialist Thomas Reiner focuses on the development of novel imaging probes for both PET imaging and optical imaging technologies.

Education

PhD, Technical University of Munich, Germany
Publications
  • Kossatz S, Pirovano G, Demétrio DSFP, Strome A, Sunny S, Zanoni D, Mauguen A, Carney B, Brand C, Shah V, Ramanajinappa RD, Hedne N, Birur P, Sihag S, Ghossein RA, Gonen M, Strome M, Suresh A, Kuriakose M, Ganly I, Patel S, Reiner T. Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers. Nature biomedical engineering. 2020;4(3):272.
  • Schöder H, França PDS, Nakajima R, Burnazi E, Roberts S, Brand C, Grkovski M, Mauguen A, Dunphy MP, Ghossein RA, Lyashchenko SK, Lewis JS, O’Donoghue JA, Ganly I, Patel SG, Lee NY, Reiner T. Safety and Feasibility of PARP1/2 Imaging with (18)F-PARPi in Patients with Head and Neck Cancer. Clin Cancer Res. 2020;26(13):3110-6.
Learn more